Description
Zydelig (Idelalisib) 100mg Online
Zydelig (Idelalisib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma. Zydelig was approved by the US Food and Drug Administration (FDA) on an “accelerated” basis. Patients in clinical studies responded to this medicine. However, it has not been shown that Zydelig can improve symptoms or lengthen survival time.
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non- Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on the Overall Response Rate. An improvement in patient survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
Zydelig is used along with another medication rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) in people whose cancer came back after receiving other cancer treatments. It is also used to treat certain types of follicular lymphoma (FL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells) in people whose cancer came back after being treated with at least 2 other cancer treatments. Idelalisib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. Approval.
